These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7677959)

  • 1. Complement activation by human monoclonal antibodies to human immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Zolla-Pazner S
    J Virol; 1993 Jan; 67(1):53-9. PubMed ID: 7677959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Spear GT; Takefman DM; Sharpe S; Ghassemi M; Zolla-Pazner S
    Virology; 1994 Nov; 204(2):609-15. PubMed ID: 7941328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement.
    Jia L; Xu Y; Zhang C; Wang Y; Chong H; Qiu S; Wang L; Zhong Y; Liu W; Sun Y; Qiao F; Tomlinson S; Song H; Zhou Y; He Y
    Virol J; 2010 Jun; 7():142. PubMed ID: 20584336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.
    Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
    Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K
    J Virol; 1995 Jun; 69(6):3333-40. PubMed ID: 7538171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.
    Burkly L; Mulrey N; Blumenthal R; Dimitrov DS
    J Virol; 1995 Jul; 69(7):4267-73. PubMed ID: 7769687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.
    Pincus SH; McClure J
    Proc Natl Acad Sci U S A; 1993 Jan; 90(1):332-6. PubMed ID: 8419938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
    J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1.
    Stoiber H; Schneider R; Janatova J; Dierich MP
    Immunobiology; 1995 Jun; 193(1):98-113. PubMed ID: 7590866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV.
    Mitchell WM; Ding L; Gabriel J
    AIDS; 1998 Jan; 12(2):147-56. PubMed ID: 9468363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.
    Verrier FC; Charneau P; Altmeyer R; Laurent S; Borman AM; Girard M
    Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9326-31. PubMed ID: 9256481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis.
    Nakamura M; Okada H; Sasaki H; Yoshida K; Kamada M; Okada N; Terada M; Ohno T
    Microbiol Immunol; 1996; 40(8):561-7. PubMed ID: 8887350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.
    Jiang SB; Lin K; Neurath AR
    J Exp Med; 1991 Dec; 174(6):1557-63. PubMed ID: 1836013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells.
    Marschang P; Gürtler L; Tötsch M; Thielens NM; Arlaud GJ; Hittmair A; Katinger H; Dierich MP
    AIDS; 1993 Jul; 7(7):903-10. PubMed ID: 7689323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.